(1) Meridian Bioscience Inc. (NASDAQ:VIVO) triggered: 01/11/2017
Meridian Bioscience is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels; the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Co. has two reportable segments: Diagnostics, which consists of manufacturing operations and the sale and distribution of diagnostic test kits; and Life Science, which consists of manufacturing operations, sale and distribution of bulk antigens.
VIVO — last trade: $17.10 — Recent Insider Buys:
John A. Kraeutler
Chairman and CEO
EVP, Pres Global Operations
Dwight E. Ellingwood
VIVO — Key Stats (updated Friday, January 13, 10:21 AM)
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.